[go: up one dir, main page]

WO2009131366A3 - Cdca5 en tant que marqueur diagnostique et agent thérapeutique pour le cancer gastrique ou le cancer colorectal - Google Patents

Cdca5 en tant que marqueur diagnostique et agent thérapeutique pour le cancer gastrique ou le cancer colorectal Download PDF

Info

Publication number
WO2009131366A3
WO2009131366A3 PCT/KR2009/002085 KR2009002085W WO2009131366A3 WO 2009131366 A3 WO2009131366 A3 WO 2009131366A3 KR 2009002085 W KR2009002085 W KR 2009002085W WO 2009131366 A3 WO2009131366 A3 WO 2009131366A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
cdca5
colorectal cancer
gastric cancer
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/002085
Other languages
English (en)
Korean (ko)
Other versions
WO2009131366A2 (fr
Inventor
염영일
이희구
윤효란
김재화
송은영
김종태
김영호
전호경
정경숙
원미선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2009131366A2 publication Critical patent/WO2009131366A2/fr
Publication of WO2009131366A3 publication Critical patent/WO2009131366A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne le biomarqueur CDCA5 (protéine associée au cycle de division cellulaire 5) qui est spécifique du cancer gastrique ou du cancer colorectal. L'invention concerne plus particulièrement une composition servant à diagnostiquer un cancer gastrique ou un cancer colorectal et contenant un agent mesurant le niveau d'expression de CDCA5, un nécessaire contenant cette composition, un procédé de détermination du marqueur, ainsi qu'un procédé de criblage d'un agent thérapeutique pour le cancer gastrique ou colorectal au moyen de ce marqueur. L'invention concerne en outre une composition pharmaceutique servant à prévenir et à traiter le cancer et contenant une matière inhibant l'expression ou l'activation de CDCA5.
PCT/KR2009/002085 2008-04-21 2009-04-21 Cdca5 en tant que marqueur diagnostique et agent thérapeutique pour le cancer gastrique ou le cancer colorectal Ceased WO2009131366A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0036865 2008-04-21
KR20080036865 2008-04-21

Publications (2)

Publication Number Publication Date
WO2009131366A2 WO2009131366A2 (fr) 2009-10-29
WO2009131366A3 true WO2009131366A3 (fr) 2010-01-21

Family

ID=41217258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002085 Ceased WO2009131366A2 (fr) 2008-04-21 2009-04-21 Cdca5 en tant que marqueur diagnostique et agent thérapeutique pour le cancer gastrique ou le cancer colorectal

Country Status (1)

Country Link
WO (1) WO2009131366A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010047028A1 (fr) * 2008-10-24 2010-04-29 Oncotherapy Science, Inc. Procédé d'analyse de composés contre le cancer du poumon ou de l'œsophage
CN107619835A (zh) * 2017-05-11 2018-01-23 广东医科大学 Cdca5在胃癌中的表达载体及其构建方法及cdca5在胃癌中特异干扰片段
CN109652548B (zh) * 2019-01-21 2022-08-05 首都医科大学附属北京朝阳医院 circ-CCNB1作为胃癌和结直肠癌诊断生物标志物和治疗靶点的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002378A2 (fr) * 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determination de genes associes au cancer et de cibles therapeutiques utilisant des methodes de cytogenetique moleculaire
US20060074565A1 (en) * 2004-10-06 2006-04-06 Miller Lance D Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
US20060194229A1 (en) * 2005-01-25 2006-08-31 Sky Genetics, Inc. Cancer markers and detection methods
WO2007013671A2 (fr) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Procédé de diagnostic du cancer de l'oesophage
US20080057514A1 (en) * 2006-09-06 2008-03-06 Vanderbilt University Methods of screening for gastrointestinal cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002378A2 (fr) * 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determination de genes associes au cancer et de cibles therapeutiques utilisant des methodes de cytogenetique moleculaire
US20060074565A1 (en) * 2004-10-06 2006-04-06 Miller Lance D Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
US20060194229A1 (en) * 2005-01-25 2006-08-31 Sky Genetics, Inc. Cancer markers and detection methods
WO2007013671A2 (fr) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Procédé de diagnostic du cancer de l'oesophage
US20080057514A1 (en) * 2006-09-06 2008-03-06 Vanderbilt University Methods of screening for gastrointestinal cancer

Also Published As

Publication number Publication date
WO2009131366A2 (fr) 2009-10-29

Similar Documents

Publication Publication Date Title
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
WO2009113814A3 (fr) Marqueur protéique utilisé pour le diagnostic précoce du cancer du foie
WO2009038689A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2010091049A3 (fr) Diagnostic et traitement du cancer
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2009012109A3 (fr) Composes contenant de la cyanine utiles dans l'imagerie et le traitement du cancer
WO2008030273A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2009085234A3 (fr) Utilisation d'un micro-arn à titre de marqueur biologique d'une activité médicamenteuse immunomodulatoire
WO2008042231A3 (fr) Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
GB2459228A (en) Exosome-associated microrna as a diagnostic marker
MY153198A (en) Inhibitors of protein aggregation
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2011002834A3 (fr) Compositions et procédés de diagnostic et de traitement du diabète de type i
MX2012004210A (es) Derivados de pirazol como moduladores del canal de calcio activado por liberacion de calcio.
EP2179037A4 (fr) Procédés permettant un diagnostic, un pronostic et procédés de traitement
EP2527466A3 (fr) Variants génétiques du CHR2 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2010062377A3 (fr) Procédés et compositions pour la détection et le traitement de l’éclampsie
WO2009100105A3 (fr) Inhibiteurs d'isoformes oncogènes et leurs utilisations
WO2010120143A3 (fr) Marqueur pronostique du cancer du foie
WO2007139815A3 (fr) Procédé d'imagerie et de thérapie utilisant des cellules progénitrices
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
WO2011052906A3 (fr) Utilisation de eif3m pour le diagnostic et le traitement du cancer
MY147634A (en) New crystalline forms
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
WO2009064927A3 (fr) Acide gras synthase phosphoryle et traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734581

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09734581

Country of ref document: EP

Kind code of ref document: A2